First-in-Human Trial of Bcma-CD19 Compound CAR with Remarkable Donor-Specific Antibody Reduction

Fang Liu,Hongyu Zhang,Xiao Wang,Yisong Xiong,Yuanzhen Cao,Yi Su,Hai Yi,Jia Feng,Wen-li Zhang,Yu Ma,Masayuki Wada,Yupo Ma

First-in-Human Trial of Bcma-CD19 Compound CAR with Remarkable Donor-Specific Antibody Reduction

2019

Fang Liu
Hongyu Zhang
Xiao Wang
Yisong Xiong
Yuanzhen Cao
Yi Su
Hai Yi
Jia Feng
Wen-li Zhang
Yu Ma
Masayuki Wada
Yupo Ma

DISCLOSURES: Ma: iCAR Bio Therapeutics Ltd: Employment. Wada:iCell Gene Therapeutics LLC: Employment. Ma:iCell Gene Therapeutics LLC: Consultancy, Equity Ownership, Research Funding; iCAR Bio Therapeutics Ltd: Consultancy, Equity Ownership, Research Funding.

Keywords:

human trial
Antibody
CD19
Pharmacology
Medicine
Coculture Technique
tumor cells
Hematological Diseases
Business administration
Immunology
single dose regimen
donor specific antibodies
complete remission
first in human
Ferrous salts

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations